BPC-157
Synthetic peptide fragment (derived from a protein identified in gastric juice)
Quick Answer
A synthetic 15-amino-acid peptide based on a fragment of a naturally occurring protein first identified in human gastric juice. Widely discussed in online fitness/recovery communities, but its research and regulatory profile is very different from that discussion implies.
Why People Are Interested
One of the most widely discussed peptides in fitness and recovery communities, largely on the strength of animal research and a large volume of anecdotal reports about tissue and joint recovery — a useful case study in exactly the gap this Evidence Snapshot exists to make visible.
What People Hope It May Do
Faster recovery from tendon, ligament, and soft-tissue injuries, and general anti-inflammatory support — all based on preclinical/animal signals and community reports, not established human clinical evidence. (Commonly discussed or proposed — not an established, evidence-backed outcome unless separately stated in Human Evidence above.)
Potential / Research Areas
Tendon, ligament, and muscle healing (animal models)
Gastrointestinal tissue protection/healing (animal models)
General anti-inflammatory pathways
How It May Work
Proposed (not established) mechanisms include promoting angiogenesis (new blood vessel formation) and modulating growth factor pathways involved in tissue repair — based primarily on animal-model research.
What Human Research Shows
Very limited. There is not a substantial base of large, controlled human clinical trials. Most human-relevant discussion in public sources comes from anecdote, small/uncontrolled reports, or extrapolation from animal data — this should always be described accurately as a major evidence gap, not glossed over.
What Preclinical Research Shows
The majority of the existing research base is rodent/animal-model studies looking at tissue healing and gut protection.
Six independent readings, not one score. This reflects the volume and stage of research and discussion — it is not a rating of safety or effectiveness.
"Real-World Interest" and "Research Momentum" reflect the volume of public discussion and research activity Element Health Labs has observed — an editorial judgment, not a measured statistic, and not a claim about clinical significance. Anecdotal popularity is not evidence of effectiveness.
What People Report
What Experts Are Saying
Curated commentary specific to BPC-157 is planned as the Expert & Creator Library grows. Being listed there does not imply an expert's endorsement of Element Health Labs.
Clinical Trials
For the current, authoritative list of registered trials involving BPC-157, search ClinicalTrials.gov directly — trial status changes frequently, and that registry is the source of truth, not a static summary on this page.
Potential Risks & Side Effects
Because large controlled human trials are lacking, a comprehensive human safety profile does not exist. This is itself an important safety-relevant fact to communicate, rather than an invitation to speculate about safety in either direction.
Regulatory Status
Not FDA-approved for any human use. Notably, the FDA has taken regulatory action specifically flagging BPC-157 as raising safety concerns in the context of compounding (it has been proposed/placed on lists restricting its use in compounded drug products in recent FDA guidance). It is often sold labeled "for research purposes only" — that label does not make retail sale for human consumption lawful, and this business will never frame or sell it that way.
Recent development (2026-08-17): On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee voted 8-6 (1 abstention) to recommend adding BPC-157 to the FDA's 503A Bulks List, which would let compounding pharmacies legally use it. This is a nonbinding advisory recommendation only — the FDA has not added BPC-157 to that list, nothing about its legal status has actually changed, and it remains not FDA-approved for any human use. The FDA must still decide whether to proceed through formal notice-and-comment rulemaking. Worth noting for context: the agency's own scientists reportedly opposed the recommendation, and a majority of the panelists who voted yes reportedly have ties to the peptide industry. Full sourcing in This Week in Peptides.
What We Still Don't Know
Whether the animal-model tissue-repair signals translate to humans at all, what an appropriate human dose would even be, and long-term safety — none of which has been established through controlled human trials.
Limitations of Evidence
Predominantly animal-model evidence; human data is sparse, often low-quality, and not sufficient to support efficacy or safety claims for human use.
Keep Researching
- Search ClinicalTrials.gov for BPC-157
- Expert & Creator Library
- This Week in Peptides
- Understanding Your Bloodwork
- Related peptides:
Last reviewed: 2026-08-17 — FDA compounding-list status re-verified (see Recent development above).